KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

K Fizazi, K N Chi, N D Shore, K Herrmann, J S de Bono, D Castellano, J M Piulats, A Fléchon, X X Wei, H Mahammedi, G Roubaud, M Fleming, T Haas, S Ghebremariam, T N Kreisl, S Rajagopalan, O Sartor, M J Morris, PSMAfore Investigators

Ann Oncol 36(11) 1319-1330

PMID40680993
PMCIDPMC12399216
DOI10.1016/j.annonc.2025.07.003
发表日期2025-07-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In PSMAfore, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated safety data. PATIENTS AND METHODS: PSMAfore (NCT04689828) was an open-label, international, phase III trial. Patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who had experienced disease progression once on a previous ARPI and were candidates for ARPI change were randomized 1 : 1 to 177Lu-PSMA-617 or ARPI change to abiraterone or enzalutamide. Crossover from ARPI change to 177Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. Endpoints included rPFS (primary), OS (key secondary), and safety (secondary). RESULTS: Patients were randomized to 177Lu-PSMA-617 or ARPI change (n = 234 each): 141/234 participants (60.3%) randomized to ARPI change crossed over (75.4% of those with centrally confirmed radiographic progression). The median OS was 24.48 months [95% confidence interval (CI) 19.55-28.94 months] with 177Lu-PSMA-617 versus 23.13 months (95% CI 19.61-25.53 months) with ARPI change [hazard ratio (HR) 0.91, 95% CI 0.72-1.14, P = 0.20] based on the intention-to-treat (ITT) principle; the crossover-adjusted OS HR by inverse probability of censoring weighting modelling was 0.59 (95% CI 0.38-0.91). For 177Lu-PSMA-617 versus ARPI change, exposure-adjusted incidences of grade ≥3 and serious treatment-emergent adverse events were 60.8 versus 85.1 and 32.5 versus 49.9 per 100 patient-treatment years, respectively. Dry mouth occurred in 135/227 participants (59.5%; 2/227 grade ≥3) and anaemia in 62/227 (27.3%; 14/227 grade ≥3) in the 177Lu-PSMA-617 arm. CONCLUSIONS: OS analyses did not show a statistically significant difference between the 177Lu-PSMA-617 and ARPI arms based on the ITT principle; results were likely confounded by the high rate of crossover. The safety profile of 177Lu-PSMA-617 was favourable with no new safety signals identified.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1.. Intention-to-treat analysis of overall survival (key secondary efficacy endpoint). ARPI, androgen receptor pathway inhibitor; CI, confidence interval; no., number; PSMA, prostate-specific membrane antigen.

KM_panel

overall survival

Figure 1 · Panel KM_panel

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel KM_panel 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2.. Incidence of haematologic TEAEs by number of 177 Lu-PSMA-617 administrations and number of bone metastases at baseline. (A) Proportion of participants with haematologic TEAEs occurring at 1–4 versus 5–6 administrations of 177 Lu-PSMA-617, among participants who received 5 or 6 administrations 177 Lu-PSMA-617 ( n = 165). (B) Proportion of participants with haematologic TEAEs according to number of bone metastases at baseline (0 a : 177 Lu-PSMA-617 n = 29, ARPI change n = 30; 1–5: 177 Lu-PSMA-617 n = 80, ARPI change n = 84; 6–20: 177 Lu-PSMA-617 n = 69, ARPI change n = 84; or >20/superscan: 177 Lu-PSMA-617 n = 49, ARPI change n = 34). Adverse events were coded using Common Terminology Criteria for Adverse Events v5.0 grading and Medical Dictionary for Regulatory Events v27.1 terms. a Participants with a nonevaluable number of lesions are counted in the ‘0 bone metastases at baseline’ subgroup. b Includes haemoglobin decreased. c Includes lymphocyte count decreased. d Includes neutrophil count decreased (panel A and B) and febrile neutropenia (panel B only). e Includes platelet count decreased. f Includes white blood cell count decreased. ARPI, androgen receptor pathway inhibitor; No., number; PSMA, prostate-specific membrane antigen; TEAEs, treatment-emergent adverse events.
非 KM Figure